List of Excipients in Branded Drug REFISSA TRETINOIN (EMOLLIENT)

Generic Drugs Containing REFISSA TRETINOIN (EMOLLIENT)

Company	Ingredient	NDC	Excipient
ZO Skin Health Inc	tretinoin	42851-012	BUTYLATED HYDROXYTOLUENE
ZO Skin Health Inc	tretinoin	42851-012	CITRIC ACID MONOHYDRATE
ZO Skin Health Inc	tretinoin	42851-012	EDETATE DISODIUM
ZO Skin Health Inc	tretinoin	42851-012	HYDROXYOCTACOSANYL HYDROXYSTEARATE

What are the Most Frequently-Used Excipients in REFISSA TRETINOIN (EMOLLIENT)?

# Of NDCs	Excipient
1	BUTYLATED HYDROXYTOLUENE
1	CITRIC ACID MONOHYDRATE
1	EDETATE DISODIUM
1	HYDROXYOCTACOSANYL HYDROXYSTEARATE

Refissa Tretinoin Emollient Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Refissa is a prescription topical cream containing 0.05% tretinoin, a retinoid used for the topical treatment of fine facial wrinkles. Its commercial value is tied less to molecule-level exclusivity than to formulation performance, irritation control, sensory properties, packaging, manufacturing consistency, and brand positioning. The principal opportunity is a differentiated topical tretinoin platform that improves tolerability without changing the active ingredient or approved use.

What is Refissa and how does its formulation work?

Refissa is an emollient cream containing tretinoin 0.05% w/w. The FDA-approved label identifies the product for topical treatment of fine facial wrinkles associated with photodamaged skin. It does not establish tretinoin as a treatment for all signs of photoaging, actinic keratoses, or hyperpigmentation under the Refissa indication. The product is prescription-only in the United States.[1]

The formulation uses a conventional oil-in-water cream system. Listed inactive ingredients include purified water, mineral oil, stearic acid, isopropyl myristate, polyoxyl 40 stearate, stearyl alcohol, xanthan gum, sorbic acid, and butylated hydroxytoluene.[1]

Product attribute	Refissa profile
Active ingredient	Tretinoin
Strength	0.05% w/w
Dosage form	Topical cream
Formulation type	Emollient cream
U.S. regulatory pathway	NDA
U.S. application	NDA 020475
Primary indication	Fine facial wrinkles associated with photodamaged skin
Drug class	Topical retinoid
Generic pathway	ANDA for pharmaceutical equivalents
Biosimilar exposure	Not applicable

The excipient system has four commercial functions:

1. It solubilizes or disperses tretinoin in the cream.
2. It creates an occlusive and emollient film on the skin.
3. It controls spreadability, residue, and patient acceptance.
4. It protects a light- and oxidation-sensitive active ingredient during shelf life.

What excipients protect tretinoin stability?

Tretinoin is sensitive to light and oxidation. Excipient selection must therefore be evaluated with packaging and manufacturing controls rather than in isolation.

Antioxidants

Butylated hydroxytoluene is listed in the Refissa formulation and is used as an antioxidant. An optimized tretinoin product may evaluate alternative antioxidants or antioxidant combinations, but any change must be supported by impurity, potency, and photostability data.

Potential development candidates include:

• Butylated hydroxytoluene
• Tocopherol
• Ascorbyl derivatives
• Chelating agents such as disodium edetate
• Low-peroxide emollients and controlled-purity oils

A higher antioxidant concentration does not automatically improve the product. Excess antioxidant can affect odor, color, skin feel, regulatory acceptability, and compatibility with packaging.

Emollients and oil-phase materials

Mineral oil provides occlusivity and reduces transepidermal water loss. Isopropyl myristate improves spreadability and can reduce the heavy feel associated with mineral-oil-rich creams. Stearic acid and stearyl alcohol contribute to cream structure, viscosity, and emollience.

Commercially relevant substitutions include:

Formulation objective	Candidate excipient direction
Lower greasiness	Light esters, caprylic/capric triglyceride, hemisqualane
Higher occlusivity	Petrolatum, hydrogenated polyisobutene, silicone elastomers
Improved spreadability	C12-15 alkyl benzoate, dicaprylyl carbonate
Sensitive-skin positioning	Lower-fragrance, lower-irritancy emollient systems
Premium sensory profile	Squalane, selected silicones, lamellar emulsions
Lower raw-material variability	Compendial mineral oils and controlled-source fatty alcohols

These changes may create a new formulation platform, but they also create new risks involving tretinoin solubility, particle size, release rate, preservative performance, and bioequivalence.

What formulation patents could protect a new Refissa competitor?

A new tretinoin product is more likely to obtain meaningful protection from formulation and process claims than from broad composition-of-matter claims. Tretinoin itself is an established active ingredient, and broad molecule-level exclusivity is no longer the principal barrier to entry.

Potential patent claim categories include:

Tretinoin solubilization

A patent may claim a specific solvent or co-solvent system that maintains tretinoin in solution or limits crystallization during storage. Relevant variables include:

• Tretinoin concentration
• Oil-phase composition
• Solvent-to-active ratio
• Water activity
• Particle size
• Crystal form
• Heating and cooling profile

Irritation-reduction systems

Topical retinoids can cause erythema, peeling, dryness, and burning. A formulation patent may claim an excipient combination that reduces irritation while maintaining tretinoin delivery.

Possible approaches include:

• Controlled-release microspheres
• Liposomes or lipid nanoparticles
• Lamellar emulsions
• Barrier-supportive lipid systems
• Humectant and occlusive combinations
• Reduced free-drug activity
• Polymer-based release modifiers

A claim directed only to "reduced irritation" may be weak unless supported by reproducible clinical or validated pharmacodynamic data.

Photostability and oxidation control

Protection may focus on the combination of antioxidant, light-blocking packaging, headspace control, and manufacturing conditions. A robust patent position could cover:

• Specific antioxidant concentrations
• Low-oxygen filling
• Nitrogen purging
• Opaque or multilayer tubes
• Airless pump systems
• Defined degradation-product limits
• Stability after repeated dispensing

Rheology and sensory performance

Viscosity, yield stress, spreadability, and residue can distinguish products that contain the same tretinoin strength. Patentable parameters may include:

• Viscosity at defined shear rates
• Droplet-size distribution
• Phase structure
• Spreadability values
• Tretinoin release profile
• Emulsion particle size
• Freeze-thaw stability

These claims require careful drafting. Numerical ranges that are not linked to a clinically relevant benefit may be vulnerable to obviousness and enablement challenges.

What is the Orange Book status of Refissa?

Refissa is an NDA product, so any applicable listed patents would be evaluated through the FDA Orange Book framework. A generic applicant seeking approval of a tretinoin cream equivalent may submit a Paragraph IV certification against an unexpired listed patent or a Paragraph III certification against a patent that has not yet expired.[2]

The commercial analysis should separate three forms of protection:

Protection category	Relevance to Refissa
Active-ingredient patent	Historical and unlikely to be the main current barrier
Refissa formulation patent	Relevant only if listed and unexpired
Method-of-use patent	Could affect the approved wrinkle-treatment indication
Regulatory exclusivity	Historical NDA protection; not a substitute for current patent rights
Trade secrets	Manufacturing, scale-up, and quality-control know-how
Trademark and brand	Refissa name, market recognition, and prescriber familiarity

An Orange Book listing does not automatically establish that a patent will block every generic product. The scope of the claims, the proposed generic formulation, and the applicant’s certification determine the practical risk.

When does Refissa lose exclusivity?

Refissa’s current competitive position is primarily post-exclusivity. Tretinoin is an established small molecule, and the relevant U.S. entry route is an ANDA rather than a biosimilar application. Generic applicants can seek approval by demonstrating pharmaceutical equivalence and bioequivalence or satisfying FDA’s applicable topical-product requirements.[2,3]

The key dates should be distinguished as follows:

Milestone	Commercial significance
NDA approval	Established the approved Refissa product
NDA regulatory exclusivity	Protected approval for the applicable statutory period
Patent expiry	Determines whether a listed patent can delay approval
First ANDA approval	Creates the first direct generic benchmark
Multiple ANDA approvals	Usually increases price competition
Formulation patent expiry	May remove a barrier to differentiated delivery systems

A precise patent-expiration date should not be inferred from the product name or NDA number. It must be taken from the current Orange Book patent listing and the underlying patent records. The product’s historic regulatory exclusivity is not itself a current barrier to generic development.

Which companies are challenging Refissa with generic tretinoin?

Generic tretinoin creams, gels, lotions, and microsphere products are commercially established in the United States. The competitive set includes manufacturers of tretinoin topical products and companies supplying contract development or manufacturing services for topical semisolids.

The main competitive groups are:

• Large generic drug manufacturers with ANDA infrastructure
• Dermatology-focused branded and generic companies
• Specialty pharmaceutical companies selling alternative tretinoin vehicles
• Contract manufacturers with semisolid scale-up capabilities
• Consumer dermatology companies developing retinoid-adjacent products

The most relevant competitive products are not limited to direct Refissa equivalents. Retin-A, Retin-A Micro, Altreno, Atralin, generic tretinoin cream, generic tretinoin gel, and generic tretinoin lotion compete through different delivery systems, strengths, indications, and tolerability profiles.

How does Refissa compare with other tretinoin formulations?

Product type	Primary differentiation	Excipient opportunity	Commercial risk
Conventional cream	Emollience and low-cost manufacture	Improve sensory profile and irritation control	High generic substitution
Gel	Faster-drying, lighter feel	Alcohol-free or low-irritancy vehicles	Dryness and irritation
Microsphere gel	Controlled release and reduced irritation positioning	Polymer particle engineering	Higher manufacturing complexity
Lotion	Cosmetic elegance and spreadability	Lightweight emulsion and humectants	Stability and preservative burden
Foam	Rapid application and low residue	Volatile and foaming systems	Packaging and process complexity
Lipid or lamellar cream	Barrier support and controlled delivery	Ceramide, fatty-acid, or phospholipid systems	More complex characterization

Refissa’s strongest commercial attribute is its emollient positioning. A competitor can target patients who discontinue tretinoin because of dryness, peeling, stinging, or poor cosmetic feel. The product must demonstrate that the new excipient system improves use without materially reducing tretinoin exposure or therapeutic performance.

What excipient strategies can create commercial opportunities?

1. Sensitive-skin tretinoin cream

A lower-irritation emollient cream could target patients who cannot tolerate conventional tretinoin products. The formulation would combine a controlled tretinoin release profile with barrier-supportive excipients.

Potential product claims could address:

• Reduced visible dryness
• Improved tolerability
• Lower stinging
• Improved patient persistence
• Better application over dry or mature skin

Clinical support is important because excipient-based tolerability claims are commercially valuable but easy for competitors to challenge.

2. Cosmetic-elegance platform

A lighter formulation could improve daytime use and reduce the perception that tretinoin is greasy. Candidate technologies include silicone-containing emulsions, lightweight esters, low-residue oils, and airless dispensing systems.

The opportunity is strongest where the product can preserve the emollient benefit while reducing shine and transfer onto clothing or bedding.

3. Stability-enhanced packaging

Packaging can be part of the product strategy. Opaque aluminum tubes, multilayer polymer tubes, airless pumps, and low-oxygen filling may improve protection from light and oxygen.

A packaging patent could cover the interaction between:

• Tube or pump construction
• Tretinoin concentration
• Headspace oxygen
• Degradation-product limits
• Dispensing dose
• In-use stability

Packaging changes may also reduce waste and improve dosing consistency.

4. Combination barrier-repair formulation

A tretinoin cream containing barrier-supportive lipids, humectants, or occlusives could be positioned for mature or sensitive skin. Candidate excipient classes include glycerin, hyaluronic acid derivatives, ceramides, cholesterol, fatty acids, panthenol, and dimethicone.

The regulatory strategy must avoid assuming that cosmetic benefits automatically support the approved drug indication. The combination must remain chemically stable and manufacturable at commercial scale.

5. Lifecycle management through new strengths and vehicles

A sponsor could pursue a lower-strength product for initiation, a higher-strength product for escalation, or a lotion and cream line serving different skin types. Each new product may generate separate formulation, method-of-use, and packaging rights.

The commercial risk is substitution by existing generic tretinoin products. A new strength or vehicle needs a clear advantage in adherence, tolerability, dosing convenience, or payer positioning.

What FDA regulatory barriers apply to a new tretinoin cream?

A conventional generic cream may use the ANDA route if it can meet the applicable requirements for pharmaceutical equivalence and bioequivalence. Complex topical products can face more demanding development requirements because formulation differences may affect local delivery even when the active ingredient and strength are identical.[3]

Key development controls include:

• Assay and content uniformity
• Tretinoin degradation products
• In vitro release testing
• In vitro permeation testing
• Microbial limits
• Preservative effectiveness
• Rheology and viscosity
• Particle or droplet-size distribution
• Container-closure compatibility
• Photostability
• In-use stability
• Scale-up reproducibility

A novel excipient may require a separate safety justification if it lacks adequate precedent for the proposed route, concentration, and exposure. FDA’s Inactive Ingredient Database can support excipient selection, but presence in the database does not guarantee approval for every concentration or dosage form.[4]

What generic entry risks exist for Refissa?

Generic entry risk is high for a conventional tretinoin 0.05% cream because the active ingredient is established and the dosage form is widely used. The strongest defenses are differentiated product performance and execution rather than reliance on the Refissa name alone.

Risk	Impact
ANDA approval of conventional cream	Direct price and volume pressure
Therapeutic substitution	Loss of prescriptions to other tretinoin vehicles
Formulary exclusion	Reduced reimbursement and slower uptake
Physician familiarity with generics	Lower switching resistance
Limited clinical differentiation	Weak premium pricing
Excipient supply disruption	Batch-release and continuity risk
Stability failure	Recall, expiry, or market withdrawal risk

A branded lifecycle product can reduce exposure by targeting patients with intolerance, dryness, poor adherence, or dissatisfaction with generic sensory properties.

What patent litigation and Paragraph IV issues affect Refissa?

A Paragraph IV challenge may trigger Hatch-Waxman litigation if an ANDA applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed.[2] The practical effect can include a 30-month stay of approval, subject to statutory conditions and court developments.

For Refissa, the litigation analysis should focus on:

• Whether any unexpired formulation patent is listed
• Whether the claims cover the generic’s excipient system
• Whether the generic uses a carve-out for a method of use
• Whether the listed patent claims a specific cream composition
• Whether the patent covers packaging or manufacturing
• Whether a settlement permits an earlier generic launch

No biosimilar litigation pathway applies because tretinoin is a synthetic small molecule, not a biologic. Patent settlements, if any, would be assessed through court filings, FDA records, and applicable antitrust disclosures rather than the biosimilar framework.

How strong is the Refissa patent estate?

The likely strength of a Refissa-centered patent estate is limited at the molecule level and potentially moderate at the formulation level. The strongest future estate would combine composition claims with stability, release, packaging, and manufacturing claims.

Estate component	Relative strategic value
Broad tretinoin composition claim	Low for a legacy product
Conventional cream claim	Low to moderate
Narrow excipient combination	Moderate if clinically differentiated
Controlled-release system	Moderate to high if difficult to design around
Photostable packaging system	Moderate
Manufacturing process	Moderate, often protected as trade secret
Method-of-use claim	Depends on claim scope and remaining term
Trademark and market identity	Commercially useful but not a generic barrier

A patent portfolio should be supported by comparative data against conventional tretinoin cream and gel products. Without evidence linking the claimed excipient system to stability, tolerability, adherence, or delivery, narrow formulation claims may face obviousness challenges.

What licensing and partnership opportunities exist?

The most attractive licensing opportunities are likely to involve enabling technologies rather than the Refissa brand itself.

Potential partners include:

• Topical drug-delivery companies with microsphere or lipid technology
• Semisolid contract development and manufacturing organizations
• Specialty dermatology companies with prescriber access
• Packaging suppliers with low-oxygen dispensing systems
• Excipient manufacturers with novel skin-barrier materials
• Generic manufacturers seeking differentiated topical products

A licensor should prioritize rights covering the United States, European Union, Japan, Canada, and major emerging markets. Geographic value will depend on local approval requirements, patent term, freedom to operate, and the availability of local generic manufacturers.

What are the key commercial opportunities by geography?

The United States offers the largest opportunity for a differentiated prescription tretinoin platform but also has the highest generic substitution risk. Europe has fragmented national markets and may favor cosmetic elegance, tolerability, and pharmacy-channel positioning. Japan and South Korea offer opportunities for premium dermatology products but require local regulatory and commercial partnerships. Emerging markets may prioritize affordability and stable room-temperature products.

Manufacturing and IP barriers differ by region:

• The United States: ANDA competition, Orange Book review, payer control
• European Union: decentralized or national approval strategies, national reimbursement
• Japan: local clinical and regulatory requirements
• China: local registration, domestic manufacturing competition, patent enforcement variability
• Latin America: country-specific registration and strong generic participation

Key Takeaways

• Refissa is a 0.05% tretinoin emollient cream approved for fine facial wrinkles associated with photodamaged skin.
• The principal commercial opportunity is improved tolerability, sensory performance, stability, or adherence.
• Tretinoin is an established small molecule, so biosimilar risk does not apply.
• Generic entry through the ANDA pathway is the primary competitive threat.
• A new product should focus on formulation, packaging, manufacturing, and method-of-use protection.
• Potentially valuable technologies include controlled release, barrier-supportive emulsions, low-irritancy excipients, and photostable packaging.
• The strongest commercial case requires comparative data showing a benefit over conventional tretinoin creams and gels.
• Exact Orange Book patent status, patent expiration dates, and settlement terms must be verified against current FDA and court records before investment or launch decisions.

FAQs About Refissa Tretinoin Excipient Strategy

Can a new tretinoin cream use the same 0.05% strength as Refissa?

Yes. A company can develop the same strength, but approval, bioequivalence, patent clearance, and labeling strategy must be assessed against the reference product and applicable FDA requirements.

Which excipients are most important for reducing tretinoin irritation?

Emollients, occlusives, humectants, barrier-supportive lipids, and controlled-release systems are the main formulation levers. Their value depends on demonstrated tolerability without unacceptable reduction in tretinoin delivery.

Is Refissa interchangeable with generic tretinoin cream?

Interchangeability depends on the specific FDA-approved product, dosage form, strength, and state substitution rules. Products with different vehicles, release properties, or approved labeling may not be operationally equivalent in every market.

Can packaging create patent protection for a tretinoin product?

Yes. Packaging claims may protect light protection, oxygen control, dose delivery, in-use stability, or compatibility with a specific tretinoin formulation. The claims must be technically specific and defensible over prior art.

Is an OTC tretinoin version a realistic commercial opportunity?

Tretinoin remains a prescription active ingredient in the United States. An OTC strategy would require a separate FDA regulatory pathway and supporting evidence for safety, labeling, and consumer use. It cannot be assumed from the existence of OTC retinol products.

References

1. U.S. Food and Drug Administration. (n.d.). Refissa (tretinoin) cream, 0.05% prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2022). Product-specific guidance for tretinoin topical products.
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.